According to a media release issued today by Nymox Pharmaceutical Corp., their investigational drug NX-1207 (now properly known by the generic name fexapotide triflutate) successfully met the designated endpoints for a Phase II clinical trial of this drug in treatment of men with low-grade, localized prostate cancer. … READ MORE …
Filed under: Drugs in development | Tagged: fexapotide, NX-1207, Nymox, outcome | 10 Comments »
As regular readers will be aware, Nymox Pharmaceutical has been developing a drug called NX-1207 for the treatment of benign prostatic hypertrophy (BPH) and for the treatment of localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: localized, NX-1207, Nymox | 1 Comment »
The Nymox Pharmaceutical Corp. seems to have decided to issue data from the Phase III clinical trial of NX-1207 in a series of media releases over time (which is a more than slightly odd way of going about such things). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: localized, low risk, NX-1207 | 2 Comments »
Now here’s an embarrassing admission for a drug development company to have to make … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: endpoint, NX-1207, outcome, Phase II, trial | 9 Comments »
Nymox Pharmaceutical Corp. has announced the initiation of patient enrollment for a Phase II trial of NX-1207 for the treatment of men with low-risk, localized prostate cancer. This product is already in Phase III clinical trials in Europe and the USA for the treatment of men with benign prostatic hyperplasia (BPH). … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: localized, low risk, NX-1207, trial | 3 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 